Events & Presentations Events & Presentations Past Events There are no past events available at this time. Presentations SITC 2019. Kirkwood, John, et al. Source Abstract 11548/085. Durable responses in anti-PD-1 refractory melanoma following intra-tumoral inje… SITC 2019. Davar, Diwakar, et al. Source Abstract 11648/034. Phase II trial of neoadjuvant nivolumab (nivo) and intra-tumoral (IT) CMP-001 i… AACR 2019. Miller, Ann, et al. Source 79(13 Suppl): Abstract 3273. CMP-001, a virus-like particle containing immunostimulatory CpG-A, for treatmen… ASCO 2018. Massa, Ryan, et al. Source 36(15 Suppl): e21507. Relationship between pre-treatment organ-specific tumor burden (TB) and respons… AACR 2018. Milhem, Mohammed, et al. Source 78(13 Suppl): Abstract CT144. Intratumoral toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with … AACR 2017. Bichat, Francis, et al. Source 77(13 Suppl): Abstract 2669. Antitumor activity of CMP-001 (TLR9 agonist) alone or combined with immune modu… ASH 2016. Lemke, Caitlin, et al. Source Blood 128(22): Abstract 3023. Combination lymphoma immunotherapy using checkpoint blockade and intratumoral v… ASCO 2016. Milhem, Mohammed, et al. Source J Clin Oncol 34: Abstract TPS9593. Phase Ib trial of the CpG-A Oligonucleotide CMP-001 combined with pembrolizumab…
Events & Presentations Past Events There are no past events available at this time. Presentations SITC 2019. Kirkwood, John, et al. Source Abstract 11548/085. Durable responses in anti-PD-1 refractory melanoma following intra-tumoral inje… SITC 2019. Davar, Diwakar, et al. Source Abstract 11648/034. Phase II trial of neoadjuvant nivolumab (nivo) and intra-tumoral (IT) CMP-001 i… AACR 2019. Miller, Ann, et al. Source 79(13 Suppl): Abstract 3273. CMP-001, a virus-like particle containing immunostimulatory CpG-A, for treatmen… ASCO 2018. Massa, Ryan, et al. Source 36(15 Suppl): e21507. Relationship between pre-treatment organ-specific tumor burden (TB) and respons… AACR 2018. Milhem, Mohammed, et al. Source 78(13 Suppl): Abstract CT144. Intratumoral toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with … AACR 2017. Bichat, Francis, et al. Source 77(13 Suppl): Abstract 2669. Antitumor activity of CMP-001 (TLR9 agonist) alone or combined with immune modu… ASH 2016. Lemke, Caitlin, et al. Source Blood 128(22): Abstract 3023. Combination lymphoma immunotherapy using checkpoint blockade and intratumoral v… ASCO 2016. Milhem, Mohammed, et al. Source J Clin Oncol 34: Abstract TPS9593. Phase Ib trial of the CpG-A Oligonucleotide CMP-001 combined with pembrolizumab…
SITC 2019. Kirkwood, John, et al. Source Abstract 11548/085. Durable responses in anti-PD-1 refractory melanoma following intra-tumoral inje…
SITC 2019. Davar, Diwakar, et al. Source Abstract 11648/034. Phase II trial of neoadjuvant nivolumab (nivo) and intra-tumoral (IT) CMP-001 i…
AACR 2019. Miller, Ann, et al. Source 79(13 Suppl): Abstract 3273. CMP-001, a virus-like particle containing immunostimulatory CpG-A, for treatmen…
ASCO 2018. Massa, Ryan, et al. Source 36(15 Suppl): e21507. Relationship between pre-treatment organ-specific tumor burden (TB) and respons…
AACR 2018. Milhem, Mohammed, et al. Source 78(13 Suppl): Abstract CT144. Intratumoral toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with …
AACR 2017. Bichat, Francis, et al. Source 77(13 Suppl): Abstract 2669. Antitumor activity of CMP-001 (TLR9 agonist) alone or combined with immune modu…
ASH 2016. Lemke, Caitlin, et al. Source Blood 128(22): Abstract 3023. Combination lymphoma immunotherapy using checkpoint blockade and intratumoral v…
ASCO 2016. Milhem, Mohammed, et al. Source J Clin Oncol 34: Abstract TPS9593. Phase Ib trial of the CpG-A Oligonucleotide CMP-001 combined with pembrolizumab…
